Comparative effectiveness research reviews are valuable resources for guiding medication use decisions, but they are underutilized, according to a recent presentation.
Comparative effectiveness research (CER) reviews are valuable resources for guiding medication use decisions but they are underutilized, according to information presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, Minneapolis.
The University of Arizona Colleges of Pharmacy and Medicine and the Arizona Health Sciences Center have developed multiple programs to disseminate information to healthcare providers on the Agency for Healthcare Research and Quality's (AHRQ) Effective Health Care Program related to CER reviews, to be used as guides in the P&T Committee formulary decision/evaluation process, as well as for other drug policy decisions in managed care plans and hospitals.
"Our training program focuses on helping clinicians obtain, evaluate, and make the best use of readily available CER reports," said Terri L Warholak, PhD, RPh, assistant professor, department of pharmacy practice and science, University of Arizona College of Pharmacy.
More information on CER process was discussed, including why CER researchers conduct studies that generate new evidence of (comparative) effectiveness for interventions (eg, medications, test, surgery, medical devices, behavior modification, etc.). This new research is used to determine the risks/harms and benefits in real-world settings of the intervention, with the aim of improving health outcomes. These evidence-based results need to be disseminated to patients, clinicians, and other healthcare decision-makers. Since CER is more of a real-world setting compared with pre-marketing clinical trials currently performed for drug approval, it is anticipated that the results generated will be more useful in policy and formulary decision-making because of its greater applicability.
Different reports are available in English and Spanish, and include: full report; summary report; clinician's guide; and patient or consumer guide. More information on the AHRQ Effective Health Care Program can be found at http://www.effectivehealthcare.ahrq.gov/index.cfm.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.